Key Points
- Sarepta Therapeutics said the U.S. Food and Drug Administration has accepted for filing supplemental new drug applications for AMONDYS 45 and VYONDYS 53.
- The applications seek to convert both medicines from accelerated approval to traditional approval.
- The FDA has set a PDUFA target action date of 28 February 2027.
- Sarepta said the filings are supported by the ESSENCE confirmatory study and substantial published real-world evidence.
- The company said both exon-skipping therapies have favourable and consistent safety profiles, based on its submission.
- Sarepta said more than 1,800 people worldwide have been treated across its exon-skipping therapies.
- The company said ESSENCE did not meet its primary endpoint, but numerical trends favoured treatment and later analyses showed increased dystrophin expression and a consistent reduction in 4-step ascend decline.
What did Sarepta announce?
Cambridge (Cambridge Tribune) June 30, 2026 — Sarepta said the FDA has accepted for filing the sNDAs for both Duchenne muscular dystrophy treatments, which means the agency will formally review the submissions.
As reported in Sarepta’s announcement, the company is seeking traditional approval for the two drugs rather than continuing only under accelerated approval. The company framed the acceptance as an important step for the Duchenne community because it begins a new phase of regulatory review.
Why is the filing significant?
The applications could strengthen the regulatory status of two long-used exon-skipping therapies for Duchenne muscular dystrophy if the FDA agrees that the evidence supports traditional approval.
Sarepta said the review package includes evidence from the ESSENCE study and years of real-world data gathered in routine use. The company also said the treatments have been used in more than 1,800 people worldwide across its exon-skipping portfolio.
What evidence is included?
The company said the submission draws on the ESSENCE confirmatory study, published real-world evidence, and safety data collected over years of use. It also said the therapies have shown preservation of muscle function and slowed disease progression in treated populations.
Sarepta said the ESSENCE study’s primary endpoint was not met, but numerical trends favoured treatment. The company added that post-hoc analyses showed increased dystrophin expression at week 96 and a consistent reduction in 4-step ascend decline across multiple analyses.
How are doctors and advocates responding?
Pat Furlong, president and founder of Parent Project Muscular Dystrophy, said the FDA’s acceptance reflects both progress in Duchenne care and the continuing need for therapies, while keeping a commitment to rigorous evaluation.
Louise Rodino-Klapac, Sarepta’s president of research and development and technical operations, said the submissions draw on ESSENCE and published real-world evidence, which she described as offering a fuller picture of how the therapies affect disease progression. She also said real-world experience is essential in very small Duchenne populations where disease damage unfolds over years.
What do the safety details say?
Sarepta said both drugs were well tolerated over 144 weeks with no new safety signals observed, according to the filing. It also said the therapies’ safety experience has been consistent with existing clinical and real-world evidence.
The release includes standard safety language for the company’s exon-skipping products, including monitoring for hypersensitivity reactions and kidney toxicity where relevant. Sarepta said these medicines are approved under accelerated approval for patients whose mutations are amenable to exon 45 or exon 53 skipping.
What happens next?
The FDA has assigned a PDUFA target action date of 28 February 2027, which is when the agency is expected to make its decision.
Until then, the review will focus on whether the submitted evidence is enough to support conversion from accelerated approval to traditional approval. Sarepta also noted in its forward-looking statements that regulatory outcomes can be affected by FDA requirements, the use of real-world evidence, and broader operational risks.
Background of this development
The company has spent more than a decade building its exon-skipping portfolio for Duchenne muscular dystrophy, including EXONDYS 51, AMONDYS 45 and VYONDYS 53. These therapies were approved under the FDA’s accelerated approval pathway, which often depends on surrogate markers rather than fully confirmed long-term clinical benefit.
Sarepta said the current sNDA strategy is grounded in confirmatory study data and real-world evidence accumulated over years of use. The company’s announcement also emphasised that the Duchenne community has been asking for regulatory pathways that remain rigorous but are flexible enough to reflect the realities of rare-disease drug development.
Prediction
If the FDA accepts the evidence and grants traditional approval, AMONDYS 45 and VYONDYS 53 may gain stronger long-term regulatory footing, which could help patient access and clinical confidence.
If the agency decides the evidence is not sufficient, the drugs could remain on their current accelerated pathway, and Sarepta may need additional data or further regulatory work. For families affected by Duchenne muscular dystrophy, the final decision may influence treatment planning, reimbursement discussions and confidence in the durability of these therapies.
